While high-dose IFN-α is the most commonly-used regimen when adjuvant IFN-α is offered to melanoma patients in the US, there is a great need for therapies with a better therapeutic index, and a variety of other regimens are currently under investigation in this setting. This evidence concerns the gene IFNA1 and melanoma.